Life Biosciences reports three glaucoma patients dosed with reprogramming therapy
- Life Biosciences said three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug.
- No serious adverse events were reported so far.
- Only the public lede was readable, so dose, follow-up length and efficacy readouts are unverified here.
💡 Points
Three patients with no serious events is a safety whisper, not a signal, but epigenetic reprogramming in humans is so new that every clean cohort moves the field's risk perception. The meaningful tests are duration of follow-up and any visual-function readout; until then this is a platform story, not a pipeline one.
STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug ↗